Developed by scientists at Cerba Healthcare on nasopharyngeal ongoing patient samples, these tools are available and efficient on clinical specimens.
Furthermore, this whole-genome sequencing in NGS assay is available for other viruses responsible for respiratory diseases like influenza viruses.
The developments reinforce Cerba Healthcare and Cerba Research's scientific commitment to the continued fight against the pandemic.
Cerba Research recently announced its In Vitro Diagnostic division supported The French Public Health Agency (Santé Publique France) in a prospective COVID-19 seroprevalence study now identified as a major partner for epidemiological studies with the French government.
Cerba Research is a healthcare diagnostic company with end-to-end drug development and diagnostic solutions to optimize R and D drug productivity and commercialization.
Providing global clinical trial central laboratory solutions (speciality lab, FCM, ICH, NGS, BioA, metabolomics), translational science (biomarkers development, CDx, biobanking), and IVD (biospecimens, prospective and retrospective sample collection, IVD evaluation).
Cerba Healthcare, the parent company of Cerba Research, is an international network of medical biology laboratories that offers a complete solution in terms of biological diagnostics, ranging from the collection centre to the speciality laboratory.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval